CV
CapsoVision, Inc.12.00
-1.78-12.9%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
562.12MP/E (TTM)
-Basic EPS (TTM)
-0.48Dividend Yield
0%Recent Filings
8-K
8-K
8-K
FDA 510(k) submission filed
CapsoVision submitted its 510(k) application to the FDA on December 29, 2025, for an AI-assisted reading module enhancing its CapsoCam Plus capsule endoscopy system. The module promises better pathology detection and shorter clinician review times. Commercialization awaits clearance. FDA approval remains uncertain.
10-Q
Q3 FY2025 results
CapsoVision posted Q3 revenue of $3.5M, up 19% y/y from $3.0M while gross margin slipped to 54% from 56% amid tariff pressures and pricing competition. YTD revenue hit $9.6M, +16% y/y, but R&D jumped 35% q/q to $6.1M on Canon CMOS development and clinical trials, driving operating loss to $8.0M (+38% y/y) and net loss to $7.9M (diluted EPS -$0.17 vs -$2.79, reconciling to 46.2M shares post-IPO). Cash swelled to $17.8M after $23.4M IPO net proceeds (July 2025), funding $15.2M YTD operating burn; no debt. Free cash flow not disclosed in the 10-Q. Supply risks loom from Asia concentration.
8-K
Q3 revenue up 19%
CapsoVision posted Q3 revenue of $3.5M, up 19% from last year, fueled by 31% new account growth and CapsoCam Plus sales. Operating expenses jumped to $9.9M on Canon CMOS development and public company costs, driving an $8.0M loss. Cash hit $17.8M post-July IPO. FDA Breakthrough submission targets pancreatic detection.
AVNS
Avanos Medical, Inc.
11.62-0.24
BSX
Boston Scientific Corporation
92.95+0.76
CBLL
CeriBell, Inc.
21.99+0.09
CVRX
CVRx, Inc.
8.32+0.14
ECIA
Encision, Inc.
0.15+0.00
ENOV
Enovis Corporation
26.07-0.47
LUCD
Lucid Diagnostics Inc.
1.12+0.01
PAVM
PAVmed Inc.
0.31-0.01
VTAK
Catheter Precision, Inc.
2.19-0.04
VYCO
Vycor Medical, Inc.
0.16+0.00